ASCO 2017 | Reporting positive treatment outcomes with bendamustine + rituximab in indolent lymphomas
Mathias Rummel
• 21 Jun 2017
Mathias Rummel, MD, PhD from Justus Liebig University, Giessen, Germany gives us an update the study of bendamustine + rituximab (BR) as first-line treatment in patients with indolent lymphomas, where it is compared with CHOP-rituximab. He describes the results of the study and his message to the medical community based on these results. Recorded at the American Society of Oncology (ASCO) 2017 Annual Meeting held in Chicago, IL.
